Navigation Links
AllCells Introduces Autoimmune Diseased Cells and Tissue Products
Date:9/11/2012

EMERYVILLE, Calif., Sept. 11, 2012 /PRNewswire/ -- AllCells, LLC, a leading provider of healthy & diseased hematopoietic tissues, primary cell types, and related services to the global life science industry has announced the release of new autoimmune diseased cells and tissue products. The specimens may be used in preclinical research, drug discovery, drug toxicity, diagnostic related assays, and other life science research applications. All products are indicated for in vitro research use only.

"The introduction of this autoimmune product line fulfills a vital need by our customers to obtain hematologic samples from a variety of autoimmune indications. These products serve as essential components of cell-based assays commonly used in the work-flow of our customers' preclinical research projects," commented Eric Martinelli, Business Development Manager.  

AllCells provides peripheral blood and/or isolated cell types from patients diagnosed with Autoimmune diseases such as  Rheumatoid Arthritis, Osteoarthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Type I & Type II Diabetes, and Multiple Sclerosis. Autoimmune plasma and peripheral blood mononuclear cells are available from each disease type.

Patient treatment history and clinical reports are available for each sample, and may include auto antibody analysis and/or clinical diagnostic scores (ACR, SLEDAI, etc.). Autoimmune Diseased Cells & Tissue products are obtained from volunteers participating in an Institutional Review Board (IRB) or Human Subject Committee approved donor program. All donors sign an informed consent form, and are screened for infectious diseases (HIV, Hepatitis B & C).

For more information about autoimmune diseased cells and tissue specimens, visit www.AllCells.com.

Full release available here:  http://www.allcells.com/blog/allcells-introduces-autoimmune-diseased-cells-and-tissue-products/.    

About AllCells, LLC
AllCells, LLC is a global biotechnology company founded in 1998 to provide researchers with a reliable supply of biologically relevant, consistent quality primary cells that enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease and stem cell research. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications where in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce time needed to isolate cells with guaranteed consistency thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements.


'/>"/>
SOURCE AllCells, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AllCells, LLC Named to Inc. Magazines 500/5000 List of Fastest Growing Companies
2. Vision Research Introduces the Newest Member Of the Phantom®- 1Mpx- v-Series Camera Family
3. JPSA Introduces Picosecond Laser Micromachining System
4. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
5. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
6. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
7. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
8. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
9. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
10. Genalyte Launches Maverick ENA Kits For Fast, Easy And Accurate Multiplexed Autoimmune Testing
11. Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):